AB Science AB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AB is a good fit for your portfolio.
News
-
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
-
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
-
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
-
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
-
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
-
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
-
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
Trading Information
- Previous Close Price
- €2.02
- Day Range
- €1.97–2.03
- 52-Week Range
- €1.55–6.54
- Bid/Ask
- €1.97 / €2.04
- Market Cap
- €98.55 Mil
- Volume/Avg
- 96,878 / 138,144
Key Statistics
- Price/Earnings (Normalized)
- 1.30
- Price/Sales
- 164.33
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 89
- Website
- https://www.ab-science.com
Comparables
Valuation
|
Metric
|
AB
|
VRDN
|
TGTX
|
|---|---|---|---|
Price/Earnings (Normalized) | 1.30 | — | 17.67 |
Price/Book Value | — | 3.46 | 13.21 |
Price/Sales | 164.33 | 2,149.37 | 8.90 |
Price/Cash Flow | — | — | 39.05 |
Price/Earnings
AB
VRDN
TGTX
Financial Strength
|
Metric
|
AB
|
VRDN
|
TGTX
|
|---|---|---|---|
Quick Ratio | 1.39 | 17.93 | 5.00 |
Current Ratio | 1.43 | 18.26 | 5.92 |
Interest Coverage | −6.34 | −137.76 | 2.04 |
Quick Ratio
AB
VRDN
TGTX
Profitability
|
Metric
|
AB
|
VRDN
|
TGTX
|
|---|---|---|---|
Return on Assets (Normalized) | −62.36% | −42.76% | 19.44% |
Return on Equity (Normalized) | — | −82.42% | 54.76% |
Return on Invested Capital (Normalized) | — | −50.70% | 35.76% |
Return on Assets
AB
VRDN
TGTX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Lhksqhkkx | Szcmsq | $70.5 Bil | |
ZTS
| Zoetis Inc Class A | Lvnsstvm | Wwmqj | $69.4 Bil | |
HLN
| Haleon PLC ADR | Yqlzcjtq | Tll | $36.6 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Vlbyvdswv | Bzkd | $14.9 Bil | |
VTRS
| Viatris Inc | Hlfftft | Nyjp | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Zzdyvbqxr | Wvtc | $12.0 Bil | |
CTLT
| Catalent Inc | Dgfsgdqz | Clmths | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Hflbhggk | Cvl | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Wjfshtzwp | Qrmg | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Vnlkqdvnk | Kzrjzr | $3.4 Bil |